ETOPOSIDE: A NEW ANTI-CANCER AGENT
- 24 October 1981
- journal article
- Published by Elsevier in The Lancet
- Vol. 318 (8252), 912-915
- https://doi.org/10.1016/s0140-6736(81)91401-x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A phase II study of oral VP-16-213 in non-seminomatous testicular cancerEuropean Journal of Cancer (1965), 1981
- VP16-213 as a single agent in advanced testicular tumorsEuropean Journal of Cancer (1965), 1980
- Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinomaEuropean Journal of Cancer (1965), 1980
- Chemotherapy of small cell carcinoma of the lung with V. P. 16–213Cancer, 1978
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesEuropean Journal of Cancer (1965), 1975
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsEuropean Journal of Cancer (1965), 1973
- 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of actionEuropean Journal of Cancer (1965), 1970
- The Cytological Effects of PodophyllinScience, 1947